Cover Image
市場調查報告書

Lupin Limited : 產品平台分析

Lupin Limited - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 240930
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
Lupin Limited : 產品平台分析 Lupin Limited - Product Pipeline Review - 2016
出版日期: 2016年07月27日 內容資訊: 英文 44 Pages
簡介

Lupin Limited是世界數一數二的學名藥廠商,專門提供心血管,氣喘,糖尿病,小兒科,腸胃系統,中樞神經系統,抗感染藥,非類固醇消炎劑,抗結核藥,頭孢菌素等領域產品。

本報告提供Lupin Limited 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Lupin Limited的基本資料

  • Lupin Limited概要
  • 主要資訊
  • 企業資料

Lupin Limited:R&D概要

  • 主要的治療範圍

Lupin Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Lupin Limited:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Lupin Limited:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

Lupin Limited:藥物簡介

  • Biosimilar for Cancer
  • LND-101001
  • LNP-1892
  • Biosimilar for Inflammation
  • Biosimilar for Ophthalmology
  • Biosimilar for Osteoporosis
  • Biosimilar for Viral Infections
  • etanercept biosimilar
  • Small Molecule for Autoimmune Diseases
  • Small Molecule for Pain and Inflammation
  • Small Molecule for Viral Infections
  • Small Molecule for Cancer
  • Small Molecule for Endocrine Disorders

Lupin Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Lupin Limited:最近的開發平台趨勢

Lupin Limited:暫停中的計劃

Lupin Limited:企業發表

Lupin Limited:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08101CDB

Summary

Global Markets Direct's, 'Lupin Limited - Product Pipeline Review, 2016', provides an overview of the Lupin Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Lupin Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Lupin Limited
  • The report provides overview of Lupin Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Lupin Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Lupin Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Lupin Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lupin Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lupin Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lupin Limited Snapshot
    • Lupin Limited Overview
    • Key Information
    • Key Facts
  • Lupin Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Lupin Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Lupin Limited - Pipeline Products Glance
    • Lupin Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Lupin Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Lupin Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Lupin Limited - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Lupin Limited - Drug Profiles
    • Biosimilar for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LND-101001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LNP-1892
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Colon and Lung Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar for Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar for Ophthalmology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar for Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Autoimmune Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Infectious Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Pain and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar for Endocrinology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lupin Limited - Pipeline Analysis
    • Lupin Limited - Pipeline Products by Target
    • Lupin Limited - Pipeline Products by Route of Administration
    • Lupin Limited - Pipeline Products by Molecule Type
    • Lupin Limited - Pipeline Products by Mechanism of Action
  • Lupin Limited - Recent Pipeline Updates
  • Lupin Limited - Dormant Projects
  • Lupin Limited - Company Statement
  • Lupin Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lupin Limited, Key Information
  • Lupin Limited, Key Facts
  • Lupin Limited - Pipeline by Indication, 2016
  • Lupin Limited - Pipeline by Stage of Development, 2016
  • Lupin Limited - Monotherapy Products in Pipeline, 2016
  • Lupin Limited - Phase III, 2016
  • Lupin Limited - Phase II, 2016
  • Lupin Limited - Phase I, 2016
  • Lupin Limited - Preclinical, 2016
  • Lupin Limited - Discovery, 2016
  • Lupin Limited - Unknown, 2016
  • Lupin Limited - Pipeline by Target, 2016
  • Lupin Limited - Pipeline by Route of Administration, 2016
  • Lupin Limited - Pipeline by Molecule Type, 2016
  • Lupin Limited - Pipeline Products by Mechanism of Action, 2016
  • Lupin Limited - Recent Pipeline Updates, 2016
  • Lupin Limited - Dormant Developmental Projects,2016
  • Lupin Limited, Other Locations
  • Lupin Limited, Subsidiaries

List of Figures

  • Lupin Limited - Pipeline by Top 10 Indication, 2016
  • Lupin Limited - Pipeline by Stage of Development, 2016
  • Lupin Limited - Monotherapy Products in Pipeline, 2016
  • Lupin Limited - Pipeline by Target, 2016
  • Lupin Limited - Pipeline by Route of Administration, 2016
  • Lupin Limited - Pipeline by Molecule Type, 2016
  • Lupin Limited - Pipeline Products by Mechanism of Action, 2016
Back to Top